MD-265

• Description:

  MD-265 is a PROTAC degrader that can break down MDM2, leading to activation of p53 in cancer cells carrying wild-type p53. MD-265 achieves complete tumor regression and improves long-term survival of mice with leukemia. (Pink: MI-1063 (HY-133754) ; Black: linker; Blue: Lenalidomide (HY-A0003) [1].

• UNSPSC:

  12352005

• Target:

  MDM-2/p53; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/md-265.html

• Smiles:

  O=C([C@H]1CC[C@@H](CC1)NC([C@@H]2NC3(CCCCC3)[C@]4(C5=CC=C(C=C5NC4=O)Cl)[C@H]2C6=CC=CC(Cl)=C6F)=O)N7CCC(C#CC8=C(C(C9=O)=CC=C8)CN9C(C(N%10)=O)CCC%10=O)CC7

• Molecular Formula:

  C50H51Cl2FN6O6

• Molecular Weight:

  921.88

• References & Citations:

  [1]Aguilar A, et al. Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia. J Med Chem. 2024 Nov 14;67 (21) :19503-19518.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2415160-21-1]